Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD

Age Related Macular Degeneration Clinical Trial

Official title: Evaluation of Genetic Variants in Patients With Type 1 Neovascularization (Sub-retinal Pigment Epithelium Neovascularization) Who Lack Typical Findings of Age Related Macular Degeneration (AMD) But Present With Findings More Consistent With Long-standing Central Serous Chorioretinopathy (CSC).

Status Completed

Clinical Trial Summary

The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.

Group 1 - CNV secondary to CSC Group 2 - CSC without CNV Group 3 - CNV secondary to advanced AMD.

Clinical Trial Description

To determine if patients presenting with type 1 neovascularization believed to be secondary to CSC are genetically distinct from typical CSC patients without neovascularization or patients presenting with choroidal neovascularization (CNV) secondary to advanced AMD. Disease associated markers detecting variants in ARMS 2, Complement Factor H (CFH) Complement component 3 (C3), Complement component 2 (C2) , Factor B (FB), VEGFA or other genetic polymorphisms associated with CNV will be evaluated to determine if the CSC neovascular group is genetically distinct from the CSC group without neovascularization or the advanced AMD group. ;

Study Design

Observational Model: Case Control, Time Perspective: Prospective

Related Conditions & MeSH terms

• Age Related Macular Degeneration
• Central Serous Chorioretinopathy
• Choroidal Neovascularization
• Macular Degeneration
• Neovascularization, Pathologic

• NCT number: NCT01880788
• Study type: Observational
• Source: Sequenom, Inc.
• Status: Completed
• Phase: N/A
• Start date: November 2012
• Completion date: August 2015